IM Cannabis to Acquire 60% Stake in Quantum Computing Bio Data Firm

Ticker: IMCC · Form: 6-K · Filed: 2025-10-23T00:00:00.000Z

Sentiment: mixed

Topics: acquisition, term-sheet, new-venture

TL;DR

IM Cannabis is buying into quantum computing bio data, a big tech pivot.

AI Summary

IM Cannabis Corp. announced on October 23, 2025, that it has signed a non-binding term sheet to acquire a 60% stake in Innovative Quantum Computing Bio Data. This potential acquisition signifies a strategic move by IM Cannabis into the quantum computing and bio data sector.

Why It Matters

This move could diversify IM Cannabis's business beyond its traditional cannabis operations, potentially opening up new revenue streams and technological advancements.

Risk Assessment

Risk Level: medium — The acquisition is based on a non-binding term sheet, meaning the deal is not yet finalized and could fall through.

Key Numbers

Key Players & Entities

FAQ

What is the nature of the business of Innovative Quantum Computing Bio Data?

The filing does not specify the exact nature of Innovative Quantum Computing Bio Data's business beyond its name suggesting involvement in quantum computing and bio data.

Is the acquisition of Innovative Quantum Computing Bio Data a binding agreement?

No, the filing states that IM Cannabis Corp. has signed a non-binding term sheet, indicating the agreement is not yet legally binding.

What is the filing date of this report?

This Form 6-K was filed on October 23, 2025.

What is the primary purpose of this Form 6-K filing?

This Form 6-K is reporting a press release dated October 23, 2025, concerning a non-binding term sheet for an acquisition.

What is IM Cannabis Corp.'s standard industrial classification?

IM Cannabis Corp.'s standard industrial classification is MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833].

From the Filing

0001178913-25-003552.txt : 20251023 0001178913-25-003552.hdr.sgml : 20251023 20251023092937 ACCESSION NUMBER: 0001178913-25-003552 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20251023 FILED AS OF DATE: 20251023 DATE AS OF CHANGE: 20251023 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IM Cannabis Corp. CENTRAL INDEX KEY: 0001792030 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40065 FILM NUMBER: 251411669 BUSINESS ADDRESS: STREET 1: KIBBUTZ GLIL YAM CITY: CENTRAL DISTRICT STATE: L3 ZIP: 4690500 BUSINESS PHONE: 416-256-4202 MAIL ADDRESS: STREET 1: KIBBUTZ GLIL YAM CITY: CENTRAL DISTRICT STATE: L3 ZIP: 4690500 6-K 1 zk2533877.htm 6-K   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of October 2025   Commission File Number: 001-40065 IM Cannabis Corp. (Exact Name of Registrant as Specified in Charter) Kibbutz Glil Yam, Central District, Israel 4690500 (Address of principal executive offices)   Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒      Form 40-F ☐   EXHIBIT INDEX   Exhibit No.   99.1 Press Release dated October 23, 2025 “IM Cannabis Signs Non-Binding Term Sheet to Acquire 60% Stake in Innovative Quantum Computing Bio Data”.     SIGNATURE   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.       IM CANNABIS CORP.     (Registrant)         Date:  October 23, 2025 By: /s/ Oren Shuster     Name: Oren Shuster     Title: Chief Executive Officer and Director   EX-99.1 2 exhibit_99-1.htm EXHIBIT 99.1 Exhibit 99.1 IM Cannabis Signs Non-Binding Term Sheet to Acquire 60% Stake in Innovative Quantum Computing Bio Data Company for Up to $54 Million TORONTO and GLIL YAM, Israel, October 23, 2025 - IM Cannabis Corp. (“ IMC ” or the “ Company ”) (Nasdaq: IMCC), a leading medical cannabis company with operations in Israel and Germany, today announced the signing of a non-binding indicative term sheet for a proposed securities exchange agreement to acquire a 60% equity interest in a pioneering quantum computing bio data company (“ The Target Company “) for aggregate consideration of up to $54 million. The Target Company specializes in utilizing quantum computing principles to store, manipulate, and analyze BIO data more efficiently than current technologies, offering groundbreaking advancements in biological data processing and analytics. Key Terms and Conditions Under the terms of the term sheet, aggregate consideration of up to $54 million, would be payable in a combination of cash, IMC shares, and potential earn-out payments tied to agreed performance milestones. The proposed transaction remains subject to the completion of due diligence, negotiation and execution of definitive agreements, receipt of all required corporate and regulatory approvals, and other customary closing conditions. There can be no assurance that any definitive agreement will be entered into or that the transaction will be completed on the terms described, or at all. This term sheet follows the Company’s decision to explore the introduction of additional business activities, with the goal of enhancing long-term growth opportunities and creating further shareholder value. No Offer or Solicitation This press release does not constitute an offer to sell or

View on Read The Filing